A U.S. court has denied Elon Musk's request for a preliminary injunction against OpenAI, the artificial intelligence company he helped fund. On Tuesday, U.S. District Judge Yvonne Gonzalez Rogers in Oakland, California, ruled against Musk, though she indicated a trial on OpenAI’s transition to a for-profit model could be expedited later this year.
Musk sued OpenAI and its CEO, Sam Altman, last year, arguing that the company had strayed from its original nonprofit mission to develop AI for the benefit of humanity. He claimed OpenAI, backed by Microsoft, is now prioritizing profits over its founding principles.
OpenAI maintains that shifting to a for-profit structure is necessary to attract the funding required for cutting-edge AI advancements. Neither Musk, OpenAI, nor Microsoft responded immediately to requests for comment on the ruling.
The case reflects growing tensions in the AI industry, where massive investments are needed to remain competitive. With the lawsuit still active, the legal battle over OpenAI’s transformation is far from over.


Ecuador Court Convicts Ex-President Lenin Moreno in Bribery Case
Jefferies Names AMEC Top China Semiconductor Equipment Pick
UN Chief Raises Concern Over US Sanctions on ICC Officials
US Judge Dismisses Gautam Adani Criminal Charges
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
Capital One Says AML Review Led to Closure of Trump Organization Accounts
Itochu Offers $1.56 Billion to Privatize Dentsu Soken
OpenAI AI Agent Swarm Behind Hugging Face Hack
Google Changes EU Spam Policy Amid Antitrust Scrutiny
Nvidia Options Price in $280 Billion Earnings Swing
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules
Prince Harry, Elton John Ordered to Pay £9.54 Million in Daily Mail Legal Costs
SEC Moves to Dismiss Insider Trading Case Against Trump-Pardoned Terren Peizer
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 



